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Abstract
Hereby, we present the case of a 54-year-old woman with 
a myeloid neoplasm associated with ETV6-PDGFRB rear-
rangement. Clinical examination revealed splenomegaly 
and hypereosinophilia was observed in peripheral blood 
(44.8 × 109 WBC/L; eosinophils: 2.24 × 103/mm3). Bone 
marrow aspirate and biopsy were hypercellular, mainly 
composed of granular cells with an increased medullary eo-
sinophilia and displayed dysplastic features. Finally, bone 
marrow cytogenetics showed a t(5;12)(q33;p13) karyotype 
in 94% metaphases with fluorescence in-situ hybridization 
(FISH) analysis. Since myeloid neoplasms associated with 
PDGFRB rearrangements are generally well sensitive to 
tyrosine kinase inhibitor, an imatinib therapy was initiated 
(400 mg/daily). Patient responded well to treatment and 
eleven months after initiation of chemotherapy, patient was 
still in hematological and cytogenetic remission.
In addition, several uncertainties related to this neoplasm 
were reviewed in the literature such as male bias, eosin-
ophilic commitment, optimal imatinib dosage regimen, de-
layed-diagnostic, natural course of the disease (and associ-
ated treatment resistance) or imatinib withdrawal in case of 
deep molecular response.
Keywords
PDGFRB, ETV6, ETV6-PDGFRB rearrangement, Eosino-
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Introduction
The upper limit of normal range of eosinophils in the 
peripheral blood is an absolute eosinophil count of 350-
500/mm3. Hypereosinophilia can further be classified 
as mild, moderate or severe according to absolute eo-
sinophils counts (up to 1500/mm3, 1500-5000/mm3 and 
superior to 5000/mm3 respectively). The first step in 
interpreting hypereosinophilia is to exclude a reactive 
eosinophilia which can be caused by a variety of sec-
ondary conditions. After a cautious exclusion of those, 
primary eosinophilia can ultimately be considered [1,2].
The World Health Organization (WHO) classification 
of tumours of hematopoietic and lymphoid tissues, re-
vised in 2008 (and updated in 2016), subclassifies pri-
mary eosinophilic disorders based on cytogenetic/mo-
lecular and histopathological findings. According to this 
classification scheme, primary eosinophilic disorders 
could be classified as chronic eosinophilic leukemia, not 
otherwise specified (CEL, NOS), Hypereosinophilic Syn-
drome (HES), idiopathic hypereosinophilia, Lymphocyt-
ic Variant Hypereosinophilia (L-HES) or eosinophilia as-
sociated with abnormalities of PDGFRA, PDGFRB,FGFR1 
or PCM1-JAK2 [1-3].
Herein, we report on the case of a 54-year-old wom-
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gin. Hematological data in peripheral blood were 44.8 × 
109 WBC/L (neutrophils: 26.4 × 103/mm3, lymphocytes: 
6.3 × 103/mm3, monocytes: 2.24 103/mm3, eosinophils: 
2.24 × 103/mm3, basophils: 0.5 × 103/mm3, metamyelo-
cytes: 2.7 × 103/mm3, myelocytes: 3.1 × 103/mm3 and 
promyelocytes: 1.35 × 103/mm3), 236 × 109 platelets/L 
and an hemoglobin level of 104 g/L (Advia2120®, Sie-
mens, Germany). Bone marrow aspirate was hypercel-
lular and mainly composed of granular cells including 
21.8% of eosinophils, 37% of neutrophils, 1.8% of baso-
phils and 24.7% of immature granulocytic cells (blasts = 
1.3%, promyelocytes = 3.9%, myelocytes = 7.4%, metamy-
elocytes = 12.1%). Dysmegakaryopoiesis (Hypo-lobulated 
megakaryocytes, micromegakaryocytes, karyorrhex-
is) was also observed in approximately 35% of all ob-
served megakaryocytes (Figure 1). Bone marrow biopsy 
showed hyper cellularity (100%), with predominance 
of granulocyte, increased eosinophils and dyspoietic 
megakaryocytes (Figure 2A). Moreover, an immunos-
taining performed on bone marrow biopsy using an-
an referred to our institution after the discovery of a hy-
perleukocytosis during a myocardial ischemia follow-up. 
Conventional cytogenetics showed a t(5;12)(q33;p13) 
karyotype in 94% metaphases with Fluorescence In-Si-
tu Hybridization (FISH) analysis confirming the presence 
of a ETV6-PDGFRB fusion gene. A therapy with imatinib 
was proposed.
We thus report the case of a patient diagnosed with 
a myeloproliferative neoplasm associated with eosin-
ophilia and rearrangement of PDGFRB with a good re-
sponse to an imatinib therapy.
Case Report
A 54-year-old woman was referred to our depart-
ment of Hematology in August 2015 with a hyperleu-
kocytosis discovered during a myocardial ischemia fol-
low-up. As a matter of fact, the patient suffered from an 
inferior ST-segment elevation myocardial infarction the 
year before presentation. Clinical examination revealed 




Figure 1: Pre-treatment blood marrow aspirate showing dyskaryopoiesis A) hypo-lobulated megakaryocytes; B) Micromega-
karyocytes; C) Karyorrhexis. May Grünwald Giemsa.
 
A B
Figure 2: Bone marrow core biopsy A) (pre-treatment) important cellularity (100%), granulocytic proliferation, increased 
eosinophils and dysmegakaryopoiesiss; B) (post-treatment) moderate cellularity (50%) without significant dysmyeloplasia, 
moderate eosinophilia. All three cell lines were represented in physiological proportion. Giemsa stain.
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Figure 3: A) (pre-treatment): FISH using a dual-color ETV6 break-apart probe; B) (pre-treatment): FISH using a dual-color 
PDGFRB break-apart probe; C) (post-treatment): FISH using a dual-color PDGFRB break-apart probe, rearrangements is no 
longer visualized (sensitivity = 1 to 2% of all analyzed nuclei). FISH was performed using unstimulated cultured bone marrow cells.
 
A B
Figure 4: Karyotype of a metaphase from bone marrow aspirate A) (pre-treatment): t(5;12) reciprocal translocation (arrows); 
B) (post-treatment): absence of t(5;12)(q33;p13) reciprocal translocation. G-banded karyotype, 300 band resolutions, of 
cultured unstimulated bone marrow cells.
of all observed metaphases (Figure 3A and Figure 3B). 
In addition, cytogenetic and molecular analyses were 
negative for t(9;22)(q34;q11.2) (FISH based on the use 
of dual fusion translocation probe and RT-PCR using the 
LighCycler® LC480, Roche, Switzerland) and JAK2V617F 
(QX200® droplet digital PCR, Bio-rad, USA). However, 
ti-CD117 and -CD34 antibodies did not reveal any signif-
icant blastic population (< 2% of all observed medullar 
cells), nor did the immunotyping (FC500® Series cytom-
eter, Beckman Coulter, USA) using anti-CD34 antibodies 
on medullar cells (< 2% of all recorded events). Medullar 
cytogenetic analysis showed a t(5;12)(q33;p13) in 94% 
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62-years-old. A gender predisposition was highlight-
ed since most of diagnosed cases are male [6,8]. The 
reasons for this male bias are still unclear and differ-
ent hypothesis have been made. First, a male-specific 
mechanism could induce double-stranded breaks in the 
PDGFRB gene (as an initial event in the development 
of the leukemia). Second, a female-specific immune or 
hormonal response against cells expressing ETV6-PDG-
FRB could block the expansion of this clonal population. 
Finally, two hits may also be required to cause the de-
velopment of the disease: a first hit with the translo-
cation and a second one attributed to an unknown 
X-linked gene [5]. Our case report is interesting as only 
few reports on female patients with this translocation 
were described before in the literature.
The fusion protein involving ETV6 and PDGFRB was 
first described in 1994 in the case of a chronic myelo-
monocytic leukemia with t(5;12)(q33;p13). Keene, et 
al. were the first group to link abnormalities of chro-
mosomes 5q and 12p with eosinophilia [5,9]. PDGFRB 
(anchored in the cellular membrane) belongs to the 
type III tyrosine kinase receptor family (including other 
important kinase such as c-KIT, FLT3 or the M-CSF re-
ceptor) while ETV6 is a transcription factor belonging to 
the ETS family members. Within the chimeric protein, 
the extracellular domain of PDGFRB is replaced by the 
pointed domain of ETV6, resulting in enforced PDGFRB 
dimerization and hence constitutive activation of the ty-
rosine kinase. The subsequent chimeric protein will ulti-
mately stimulate hematopoietic cell proliferation [6,10-
12]. Another important aspect of the chimeric protein 
concerns its physico-chemical properties. When com-
pared to wild-type receptor, PDGFR chimeric protein 
is more stable and more resistant to degradation due 
to decreased ubiquitination and proteasomal degrada-
tion. This increased stability combined with constitutive 
tyrosine kinase activity promote cell proliferation [13]. 
Since the translocation discovery, more than 30 differ-
ent partners for PDGFRB were observed; some of them 
are presented in Table 2 [6,14,15].
Using Ba/F3 cells lines or CD34+ hematopoietic stem 
cells in the absence of growth factor, PDGFRB-ETV6 
was shown to activate distinctive signal transduction 
pathways such as Mitogen-Activated Protein Kinases 
(MAPK), Phosphatidylinositol-3 Kinase (PI3K) and the 
transcription factors STAT1, STAT5 and nuclear fac-
tor-κB. In addition, experiments based on the use of 
CD34+ PDGFRB-ETV6+ cells lines showed a strong com-
mitment towards the eosinophilic lineage in liquid cell 
cultures as it is the case with many patients in vivo [16]. 
One hypothesis could be the presence of numerous 
genes of importance in the proliferation and differen-
tiation of eosinophils in the 5q31-5q35 chromosomal 
region (IL-3, IL-4, IL-5, IL-13 and GM-CSF). Those genes 
could be dysregulated in the presence of chromosomal 
rearrangements and lead to a hyper proliferation of the 
eosinophilic lineage [17].
an extrachromosomal element was highlighted in 100% 
of all observed metaphases. Further analysis identified 
this extra chromosome as constitutional and karyotype 
could then be defined as 47, XX, t(5;12)(q33;p13), +mar 
c[26]/47, XX, +mar c[2] (Figure 4A). Based on all results, 
a diagnostic of myeloid neoplasms with eosinophilia 
and ETV6-PDGFRB rearrangement was made.
Our patient responded well to a hydroxyurea during 
the first month with a significant decrease in spleen size 
and reduction of WBC (including eosinophilia). Treat-
ment with imatinib mesylate was then initiated at a 
dose of 100 mg/daily, which was progressively increase 
as described in Table 1 to 400 mg/day without signif-
icant adverse effects. Two months after diagnosis and 
initiation of treatment, peripheral blood count showed 
disappearance of eosinophilia and normal leukocyte 
count.
As part of follow-up, a bone marrow aspirate and bi-
opsy were performed in September 2016. Bone marrow 
biopsy showed a cellularity of 50% without obvious his-
tological signs of dysplasia. However, a discrete eosin-
ophilia was observed (Figure 2B). Concerning the bone 
marrow aspirate, dysmegakaryopoiesis was not visual-
ized anymore and a medullary eosinophilia of 5.4% was 
assessed (blast = 1.8%). Finally, the t(5;12)(q33;p13) was 
no longer observed using FISH analysis (Figure 3C). In 
conclusion, the 54-year-old patient was assumed to be 
in hematological and cytogenetic remission 11 months 
after initiation of treatment. Interestingly, imatinib dos-
age was reduced in April 2017 to 200 mg/daily due to 
fatigue and diarrhea.
Discussion
According to the 2008 WHO classification (revised in 
2016) of tumours of hematopoietic and lymphoid tis-
sues, the patient falls into the newly proposed category 
“myeloid neoplasm associated with PDGFRB rearrange-
ment” [1,3]. Prior to this classification update, these 
neoplasms were often classified as (myelodysplastic)/
myeloproliferative disorders such as Chronic Myelo-
monocytic Leukemia (CMML), Juvenile Myelomonocytic 
Leukemia (JMML), Atypical Chronic Myeloid Leukemia 
(ACML), myelodysplasia, eosinophilic leukemia or acute 
myeloid leukemia [2,4-7].
The incidence of patients with PDGFRB rearrange-
ment is low and accounts for approximately 1.8% of 
myeloproliferative neoplasms [8]. Depending on case 
reports and reviews, median age at diagnostic for PDG-
FRB rearrangement may vary significantly from 42 to 
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Table 2: Different PDGFRB gene fusion partners observed in the literature.
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gene located at 8q24) [24]. In addition, due to the ac-
cumulation of those cytogenetic abnormalities, patients 
stop responding to conventional therapies (i.e. tyro-
sine kinase inhibitors) during AC and BC, hence those 
patients require other therapeutic approaches. Finally, 
cases of imatinib resistance were described even in the 
absence of any cytogenetic evidence of clonal evolution, 
suggesting the presence of potential unknown mutation 
which cannot be identified by conventional cytogenetic 
analysis [18].
Moreover, complications can also be caused by a po-
tential associated chronic eosinophilia which can lead 
to dysfunction of virtually any organ or organ system 
including cardiovascular, gastrointestinal, renal, der-
matologic, nervous, and upper/lower respiratory sys-
tems [18,25]. Concerning the case-report, it could be 
hypothesized that the heart attack the year before the 
diagnosis of leukemia could be partly attributed to the 
hypereosinophilia state. Indeed, eosinophilic count was 
already at the upper limit of normal range (500/mm3). 
Unfortunately, this was not investigated at this time. 
Last, patients can also die from treatment-related com-
plications (e.g. immunocompromised-related or trans-
plant complications) [7].
In case of deep molecular response, trials have 
shown that CML patients could cease their chemo-
therapy without risk of relapsing [26]. However, unlike 
FIP1L1-PDGFRA+ chronic eosinophilic leukemia, it is not 
yet known if treatment discontinuation could be con-
sidered or not for neoplasms associated with PDGFRBs 
rearrangements. Indeed, imatinib discontinuation in 
FIP1L1-PDGFRA+ patients has been related to haema-
tological relapses [2,27]. However, insufficient data are 
currently available to evaluate the potential for imatinib 
withdrawal for patients diagnosed with neoplasm asso-
ciated with PDGFRB rearrangements [28].
According to Steer et al., in a compilation of case-re-
ports, the 2-year survival rate of the 19 evaluable pa-
Clinical findings in patients with PDGFRB rearrange-
ment are heterogeneous. At diagnosis, patients can 
either be asymptomatic or complain of nonspecif-
ic constitutional symptoms such as fatigue or weight 
loss. Skin involvement was also described [17]. Physi-
cal examination reveals mild to massive splenomegaly 
for most patients while hepatomegaly is less common. 
CBC counts usually show a hyperleukocytosis together 
with hypereosinophilia in peripheral blood and/or bone 
marrow. However, absence of hypereosinophilia can 
be observed as well. Monocytosis is less common but 
frequently present. As it was the case here, bone mar-
row aspirate are generally hypercellular together with a 
granulocytic hyperplasia. However, cases of dry tap are 
reported [4,5,18,19].
First-line treatments in patient with ETV6-PDGFRB 
rearrangements include tyrosine kinase inhibitor (i.e. 
imatinib mesylate) and are associated with a good clin-
ical, cytological and molecular response [4,7,19]. How-
ever, as demonstrated in Table 2 and Table 3, dose of 
imatinib widely vary between reported patients ranging 
from 200 mg to 800 mg daily reflecting the uncertainty 
of physician regarding the optimal dose to be used in 
this disorder. Resistance to conventional therapy is dis-
cussed below.
The follow-up of patients diagnosed with a myeloid 
neoplasm associated with a t(5;12)(q33;p13) is a crucial 
issue. In different case reports, similarities were found 
between the natural course of myeloid neoplasms as-
sociated with PDGFRs rearrangements and the three 
phases of Chronic Myeloid Leukemia (CML): A Chronic 
Phase (CP), An Accelerated Phase (AP) and A Blast Cri-
sis (BC). Without successful early diagnosis and/or fol-
low-up, the disease can ultimately evolve into BC [20-
23]. The evolution to BC is characterized by an accumu-
lation of cytogenetic abnormalities such as trisomy of 
chromosome 8 [18,23]. Such trisomy was also described 
in the natural course of CML and associated with poorer 
prognosis (associated with overexpression of the myc 
Table 3: Response to tyrisine kinase (i.e. imatinib mesylate) in patients with myeloid neoplasms associated with ETV6-PDGFRB 
rearrangement.








Apperley, et al. [17] 4/0 4/0 From 400 to 800 mg/
daily
• No residual disease at 9 to 12 months after 
the initiation of the treatment
David, et al. [36] 10/2 8/4 From 200 to 800 mg/
daily
• Hematological response: 49 months (19-
60 months)
• Cytogenetic response: 47 months (16-59 
months)
• 10 patients were still alive at the time of 
publication (including all ETV6-PDGFRB 
patients)
Arefi, et al. [8] 8/2 2/8 400 mg/daily • 7 patients achived complete cytologic 
and hematological reponse including both 
ETV6-PDGFRB patients - median follow-
up = 19 months
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3. Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, et al. 
(2016) The 2016 revision to the World Health Organization 
classification of myeloid neoplasms and acute leukemia. 
Blood 127: 2391-2405.
4. Pitini V, Arrigo C, Teti D, Barresi G, Righi M, et al. (2007) 
Response to STI571 in Chronic Myelomonocytic Leukemia 
with Platelet Derived Growth Factor Beta Receptor Involve-
ment: A new case report. Haemotologica 88: 78-79.
5. Steer EJ, Cross NC (2002) Myeloproliferative disorders 
with translocations of chromosome 5q31-35: role of the 
platelet-derived growth factor receptor Beta. Acta Haema-
tol 107: 113-122.
6. Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Mi-
randa RN (2015) Hematolymphoid Neoplasms Associated 
With Rearrangements of PDGFRA, PDGFRB, and FGFR1. 
Am J Clin Pathol 144: 377-392.
7. Wittman B, Horan J, Baxter J, Goldberg J, Felgar R, et 
al. (2004) A 2-year-old with atypical CML with a t(5;12) 
(q33;p13) treated successfully with imatinib mesylate. Leuk 
Res 28: S65-S69.
8. Arefi M, Garcia J, Penarrubia M, Queizan JA, Hermosin 
L, et al. (2012) Incidence and clinical characteristics of 
myeloproliferative neoplasms displaying a PDGFRB rear-
rangement. Eur J Haematol 89: 37-41.
9. Keene P, Mendelow B, Pinto MR, Bezwoda W, MacDougall 
L, et al. (1987) Abnormalities of chromosome 12p13 and 
malignant proliferation of eosinophils: a nonrandom associ-
ation. Br J Haematol 67: 25-31.
10. Heldin CH, Lennartsson J (2013) Structural and Function-
al Properties of Platelet-Derived Growth Factor and Stem 
Cell Factor Receptors. Cold Spring Harb Perspect Biol 5: 
009100.
11. Jones AV, Cross NC (2004) Oncogenic derivatives of plate-
let-derived growth factor receptors. Cell Mol Life Sci 61: 
2912-2923.
12. Wang Q, Dong S, Yao H, Wen L, Qiu H, et al. (2014) ETV6 
mutation in a cohort of 970 patients with hematologic malig-
nancies. Haematologica 99: e176-e178.
13. Toffalini F, Kallin A, Vanderberghe P, Pierre P, Michaux 
L, et al. (2009) The Fusion Protein TEL-PDGFRB and 
FIP1L1-PDGFRA Escape Ubiquitination and Degradation. 
Haematologica 94: 1085-1093.
14. Golub TR, Barke GF, Lovett M (1994) Fusion of PDGF re-
ceptor beta to a novel ets-like gene, tel, in chronic myel-
omonocytic leukemia with t(5;12) chromosomal transloca-
tion. Cell 77: 307-316.
15. Maccaferri M, Pierini V, Di Giacomo D, Zucchini P, Forghieri 
F, et al. (2016) The importance of cytogenetic and molec-
ular analyses in eosinophilia-associated myeloproliferative 
neoplasms: an unusual case with normal karyotype and 
TNIP1- PDGFRB rearrangement and overview of PDGFRB 
partner genes. Leukemia & Lymphoma 58: 489-493.
16. Montano-Almendras C, Essaghir A, Schoemans H, Varis 
I, Noel LA, et al. (2012) ETV6-PDGFRB and FIP1L1-PDG-
FRA stimulate human hematopoietic progenitor cell prolif-
eration and differentiation into eosinophils: the role of nu-
clear factor-Κb. Haematologica 97: 1064-1072.
17. Apperley JF, Guardembas M, Melo J, Russel Jones R, Bain 
B, et al. (2002) Response to imatinib mesylate in patients 
with chronic myeloproliferative diseases with rearrange-
ments of the platelet-derived growth factor receptor beta. N 
Engl J Med 347: 481-487.
18. Han X, Medearos L, Abruzzo L, Jones D, Lin P (2006) 
tients (19 cases of myeloid leukemia associated with 
t(5;12)) was only 47% while the median survival was 
estimated to 20 months. However, some criticism can 
be brought to those results since they may potentially 
be biased. Indeed, first, some case reports presented 
patients who were suspected to be in AP or BC at di-
agnosis, worsening their survival rate. Second, due to 
misdiagnosis (e.g. schistosomiasis diagnosed as contact 
dermatitis instead of eosinophilic infiltration), some pa-
tient did not receive appropriate treatment in due time. 
Finally, imatinib was not always available since some of 
the case reports were described before the official re-
lease of the drug on the market. In addition, a recent 
retrospective study based on 26 patients (18 ETV6-PDG-
FRB and 8 others PDGFRB rearrangements) described 
a 10-year overall survival rate of 90% (95% CI 64-97%) 
with a median follow up of 10.2 years (1.8-17 years). 
Once again, due to the rarity of the disease, a publica-
tion bias cannot be excluded [28].
Conclusion
In conclusion, we reported here the case of a patient 
diagnosed with a myeloproliferative neoplasm associat-
ed with eosinophilia and rearrangement of PDGFRB with 
a good response to an imatinib therapy (400 mg/daily). 
Although imatinib has proven to be an effective thera-
peutic approach, this mini-review highlighted some dif-
ficulties associated with this neoplasm. Firstly, diagnosis 
is not always an easy task and may be time-consuming, 
leading to morbidity associated with chronic eosin-
ophilia and inappropriate treatment. Moreover, de-
layed-treatment can result in disease progression (i.e. 
accelerated or blast phase). Secondly, natural course of 
the disease (and other potential unknown mutations) 
can decrease or stop the therapeutic effectiveness of 
tyrosine kinase inhibitors. Thirdly, insufficient data are 
now present in the literature to define the optimal ty-
rosine kinase inhibitor (i.e. imatinib) dosage and the 
possibility of treatment withdrawals at hematological 
and molecular remission state. Finally, further studies 
will be necessary to better understand the physiological 
process and the genetics underlying this neoplasm (e.g. 
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